Mineralys Therapeutics to Announce Third Quarter 2026 Financial Results and Host Conference Call on Wednesday, November 4, 2026
Globe Newswire•28/10/2026•16:05 ET
0
Key Highlights
- ➤Mineralys (MLYS) will report Q3 2026 financial results after markets close November 4.
- ➤Conference call scheduled for November 4, 2026, at 4:30 p.m. ET.
- ➤Lorundrostat remains Mineralys’ investigational oral aldosterone synthase inhibitor candidate.
RADNOR, Pa., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in comorbid conditions such as chronic kidney disease, obstructive sleep apnea and other diseases driven by dysregulated aldosterone, announced it will report its financial results from the third quarter ended September 30, 2026, after the financial markets close on Wednesday, November 4, 2026.
Wednesday, November 4 (th)@ 4:30 p.m. ET Domestic:1-877-704-4453 International:1-201-389-0920 Conference ID:13762560 Webcast: Link
Get started
Create a free account to read the full story.